A coalition establishes a secure, direct link between a physical tablet and a digital backend for supply chain integrity.
A supply-chain simulation has demonstrated a secure, direct link between a physical tablet (placebo) and a digital backend, without having to rely on the traditional approach of authenticating traditional packaging barcodes.
The demonstration, conducted by PwC Australia, Colorcon, and TruTag Technologies, tested the mass digitalization of pharmaceutical tablets and their linkage to a Trillian-based trust ledger showing, the companies reported in a press statement, a step toward ensuring supply-chain integrity and addressing the problem of patient non-adherence.
The solution features three components: a Colorcon coating system infused with spectrally-encoded particles-or TruTags-that act as edible barcodes, a cell phone-based authentication application to decode and verify the embedded TruTags and link the physical tablet to the third component, a Trillian-based distributed ledger operated by PwC Australia.
“Verifiable data ledger technology offers a new means of securing and sharing information. However, these systems are still reliant on ensuring a secure link via a crypto anchor between the physical and digital world,” said Trent Lund, partner at PwC Australia New Ventures in a Dec. 10, 2019 press statement. “TruTags are a perfect crypto-anchor for directly marking pharmaceuticals and foods.”
“This technology represents a new era of security and transparency for the pharmaceutical industry in which patients can be empowered to authenticate their own medicines,” said Michael Bartholomeusz, chief executive officer of TruTag Technologies, in the press statement.
“Intelligent coatings represent an incredible opportunity for patient communication and data collection,” said Kelly Boyer, general manager, film coatings of Colorcon, in the press statement. “This technology represents a new era of security and transparency for the pharmaceutical industry in which patients can be empowered to authenticate their own medicines”.
The results of the demonstration have been published in a whitepaper.
Source: Colorcon
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.